Clinical Trials on Advanced Cholangiocarcinoma

Total 6486 results

National Cancer Institute (NCI)

Completed

Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors

Epithelioid Mesothelioma | Cholangiocarcinoma, Extrahepatic | Neoplasms With Mesothelin Expression | Adenocarcinoma, Pancreatic

United States
Virogin Biotech Canada Ltd

Recruiting

An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Hepatocellular Carcinoma | Intrahepatic Cholangiocarcinoma

United States
TriSalus Life Sciences, Inc.

Active, not recruiting

Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors

Hepatocellular Carcinoma | Intrahepatic Cholangiocarcinoma

United States
Azienda Ospedaliera di Padova

Unknown

Liver Transplantation for Hilar Cholangiocarcinoma in Association With Neoadjuvant Radio- and Chemo-therapy

Primary Sclerosing Cholangitis | Hilar Cholangiocarcinoma

Italy
Institut für Klinische Krebsforschung IKF GmbH...

Active, not recruiting

Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer

Intrahepatic Cholangiocarcinoma | Hilar Cholangiocarcinoma | Distal Cholangiocarcinoma | Gall Bladder Carcinoma | Biliary Tract Cancer (CCA)

Germany
National Cancer Institute (NCI)

Terminated

Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers

Advanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Recurrent Extrahepatic Bile Duct Cancer | Recurrent Gallbladder Cancer | Unresectable Extrahepatic Bile Duct Cancer | Unresectable Gallbladder Cancer | Cholangiocarcinoma... and other conditions

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers

Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8 | Stage III Gallbladder Cancer AJCC v8 | Stage IIIA Gallbladder Cancer AJCC v8 | Stage IIIB Gallbladder Cancer AJCC v8 | Unresectable Extrahepatic... and other conditions

United States
Zhang Xiaofeng,MD
Zeno Therapeutics Pte. Ltd

Not yet recruiting

Early Phase I Study of Autologous T Cells (EX02 CAR-T) for Unresectable Pancreatic/Bile Duct Cancer

Pancreatic Cancer | Advanced Biliary Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

MRI-based Clinico-radiomics Predicting Lymph Node Metastasis Status of Hilar Cholangiocarcinoma

Hilar Cholangiocarcinoma

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Ramucirumab in Treating Patients With Advanced or Metastatic, Previously Treated Biliary Cancers That Cannot Be Removed by Surgery

Cholangiocarcinoma | Liver and Intrahepatic Bile Duct Carcinoma | Unresectable Gallbladder Carcinoma | Stage III Gallbladder Cancer AJCC v7 | Stage IIIA Gallbladder Cancer AJCC v7 | Stage IIIB Gallbladder Cancer AJCC v7 | Stage IV Gallbladder Cancer AJCC v7 | Stage IVA Gallbladder Cancer AJCC v7 | Stage... and other conditions

United States
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
First Affiliated Hospital of Jinan University; Shenzhen University General...

Recruiting

Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma

Carcinoma | Digestive System Neoplasms | Intrahepatic Cholangiocarcinoma | First-line Treatment | PD-1 Inhibitor

China
Seoul National University Hospital

Completed

Effect of PVE on Surgical Outcomes and Long-term Survival in Perihilar Cholangiocarcinoma

Biliary Tract Cancer | Portal Vein Embolization

Korea, Republic of
Medivir

Active, not recruiting

A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations

Hepatocellular Carcinoma | Intrahepatic Cholangiocarcinoma | Liver Metastases

Korea, Republic of, Spain, Belgium, United Kingdom
National Cancer Institute (NCI)

Completed

Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer

Advanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Recurrent Extrahepatic Bile Duct Cancer | Recurrent Gallbladder Cancer | Unresectable Extrahepatic Bile Duct Cancer | Unresectable Gallbladder Cancer | Adult Primary Hepatocellular... and other conditions

United States
Amsterdam UMC, location VUmc

Completed

Optimization of Systemic Treatment Strategies in Elderly Patients With Advanced Solid Malignancies (OptiMal)

Colorectum Advanced Malignancies | Breast Advanced Malignancies | Prostate Advanced Malignancies

Netherlands
University of Zurich

Withdrawn

Response of Hepatic Tumors to Radioembolization (RESRAD)

Hepatocellular Carcinoma | Intrahepatic Cholangiocarcinoma | Liver Metastasis

Switzerland
Relay Therapeutics, Inc.

Active, not recruiting

REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors

Cholangiocarcinoma | Intrahepatic Cholangiocarcinoma | FGFR2 Gene Mutation | FGFR2 Amplification | FGFR2 Gene Fusion/Rearrangement | FGFR2 Gene Translocation | FGFR2 Gene Activation | Other Solid Tumors, Adult

United States, France, Italy, United Kingdom, Korea, Republic of, Spain, Taiwan, Sweden, Germany, Netherlands, Singapore, Australia, Hong Kong
Genoscience Pharma

Terminated

Study of GNS561 in Patients With Liver Cancer

Hepatocellular Carcinoma | Cholangiocarcinoma, Intrahepatic

France, United States, Belgium
West China Hospital

Not yet recruiting

Cadonilimab Combined With Liposomal Irinotecan Plus Leucovorin and Fluorouracil for Advanced Cholangiocarcinoma

Cholangiocarcinoma
National Cancer Institute, Naples

Recruiting

Neo-adjuvant Chemo and Immunotherapy in The Pre-operAtive Treatment of Locally Advanced cholangIOcarciNoma

Cholangiocarcinoma

Italy
Power Life Sciences Inc.

Not yet recruiting

Evaluation of the Patient's Experience in Medical Studies for Cholangiocarcinoma

Cholangiocarcinoma
Henan Cancer Hospital

Not yet recruiting

PD-1 Inhibitor Sintilimab Combined With Capecitabine for Adjuvant Treatment After Radical Resection of Cholangiocarcinoma. (SCRCA)

Cholangiocarcinoma
Khon Kaen University

Recruiting

Neoadjuvant mFOLFOXIRI for Potentially Resectable Cholangiocarcinoma

Cholangiocarcinoma

Thailand
First People's Hospital of Hangzhou
Xijing Hospital; Changhai Hospital; Cancer Institute and Hospital, Chinese Academy... and other collaborators

Completed

RFA Combined With Chemotherapy for Unresectable Cholangiocarcinoma

Cholangiocarcinoma

China
D. Kim Turgeon, MD
University of Washington

Completed

Fluorescence QRH-882260 Peptide Imaging in the Bile Duct

Cholangiocarcinoma

United States
Siriraj Hospital
Mahidol University

Unknown

The Adoptive Immunotherapy for Solid Tumors Using Modified Autologous Cytokine-induced Killer Cells

Cholangiocarcinoma

Thailand
Immunitor LLC

Unknown

Trial of Therapeutic Vaccine in Patients With Cholangiocarcinoma (cholangio)

Cholangiocarcinoma

Mongolia
ASLAN Pharmaceuticals

Completed

ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy

Cholangiocarcinoma

Taiwan, Korea, Republic of, Singapore
Roswell Park Cancer Institute
Genentech, Inc.

Completed

A Study of Gemcitabine, Capecitabine and Bevacizumab to Treat Cancer of the Gall Bladder or Bile Ducts

Cholangiocarcinoma

United States
Weill Medical College of Cornell University

Terminated

Photodynamic Therapy (PDT) Trial for Palliation of Cholangiocarcinoma (PDT)

Cholangiocarcinoma

United States
Asan Medical Center

Completed

S-1 and Photodynamic Therapy in Cholangiocarcinoma

Cholangiocarcinoma

Korea, Republic of
University of Ulm
Heidelberg University

Completed

Comparison of Biliary Forceps Biopsy and Brush Cytology

Cholangiocarcinoma

Germany
Delcath Systems Inc.

Active, not recruiting

Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma

Bile Duct Cancer | Intrahepatic Cholangiocarcinoma

United States
Sun Yat-sen University

Active, not recruiting

Adjuvant Immunotherapy Combined With Chemoradiation for Patients With High-risk reseCtable Extrahepatic chOlangiocaRcinoma and gallblaDder Cancer (ACCORD)

Biliary Tract Cancer | Gallbladder Cancer | Extrahepatic Cholangiocarcinoma

China
TransThera Sciences (Nanjing), Inc.

Recruiting

Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma (FIRST-308)

Cholangiocarcinoma

Korea, Republic of, Spain, United States, Taiwan, Italy, France, Belgium, Germany, Portugal, United Kingdom, Austria, Poland, Netherlands
Tata Memorial Hospital

Recruiting

Chemo Alone or in Combination With Radiation in Unresectable Cholangiocarcinoma

Cholangiocarcinoma

India
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Pemigatinib in Treating Patients With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Rearrangement

Cholangiocarcinoma

China
EpicentRx, Inc.

Terminated

RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration of First-Line Therapy (EPIC)

Cholangiocarcinoma

United States
University of New Mexico

Terminated

Chart Review: Unresectable/Metastatic Cholangiocarcinoma Treated With Irinotecan, Capecitabine and Celecoxib

Cholangiocarcinoma

United States
Georgetown University

Active, not recruiting

Study of Pembrolizumab and Olaparib in Bile Duct Cancer

Cholangiocarcinoma

United States
Incyte Corporation

Completed

Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)

Cholangiocarcinoma

United States, France, Italy, United Kingdom, Germany, Taiwan, Spain, Belgium, Israel, Korea, Republic of, Japan, Thailand
American University of Beirut Medical Center
Bristol-Myers Squibb

Terminated

A Study of BMS-936558 With SBRT After Induction Chemotherapy in Cholangiocarcinoma

Cholangiocarcinoma

Lebanon, Belgium, Luxembourg
Central Hospital, Nancy, France

Unknown

the Impact of Early Palliative Care on the Survival of Locally Advanced and / or Metastatic Cholangiocarcinoma Patients

Cholangiocarcinoma

France
Vejle Hospital

Completed

Combined Biological Treatment and Chemotherapy for Patients With Inoperable Cholangiocarcinoma

Cholangiocarcinoma

Denmark
International Group of Endovascular Oncology

Unknown

International Registry on Cholangiocarcinoma Treatment (CHOLANGIO)

Cholangiocarcinoma

Italy
PrECOG, LLC.
Celgene Corporation

Completed

Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Cholangiocarcinoma (PrE0204)

Cholangiocarcinoma

United States, Austria
National Cancer Center, Korea
Dong-A Pharmaceutical Co., Ltd.

Completed

A Study of Gemcitabine as an Adjuvant Treatment for Cholangiocarcinoma After Surgical Resection

Cholangiocarcinoma

Korea, Republic of
The First People's Hospital of Changzhou

Active, not recruiting

Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cholangiocarcinoma

Cholangiocarcinoma

China
University of Alabama at Birmingham
Society of Abdominal Radiology

Completed

The Role of Gadoxetate (Eovist) Enhanced CT in Evaluating Cholangiocarcinoma

Cholangiocarcinoma

United States
H. Lee Moffitt Cancer Center and Research Institute
BTG International Inc.

Completed

Study Of Intrahepatic Arterial Injection of 90-Y Glass Microspheres for Cholangiocarcinoma

Cholangiocarcinoma

United States

Clinical Trials on Advanced Cholangiocarcinoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Luxembourg

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations